UroGen Pharma Ltd.
URGN
$19.44
-$0.345-1.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.85% | 8.98% | 9.29% | 15.64% | 17.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.85% | 8.98% | 9.29% | 15.64% | 17.22% |
| Cost of Revenue | 25.48% | 7.47% | -5.13% | -6.88% | -4.24% |
| Gross Profit | 9.21% | 9.15% | 11.13% | 18.74% | 20.26% |
| SG&A Expenses | 35.89% | 32.91% | 28.71% | 22.68% | 18.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.58% | 29.44% | 25.52% | 16.58% | 11.05% |
| Operating Income | -53.68% | -54.35% | -46.00% | -17.59% | -5.13% |
| Income Before Tax | -37.55% | -34.77% | -26.16% | -6.71% | -1.93% |
| Income Tax Expenses | 5.33% | -19.81% | -27.76% | 434.70% | 167.28% |
| Earnings from Continuing Operations | -36.43% | -32.70% | -24.09% | -9.78% | -4.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.43% | -32.70% | -24.09% | -9.78% | -4.16% |
| EBIT | -53.68% | -54.35% | -46.00% | -17.59% | -5.13% |
| EBITDA | -54.42% | -55.54% | -47.30% | -18.36% | -5.64% |
| EPS Basic | -7.26% | 6.09% | 18.28% | 30.31% | 34.33% |
| Normalized Basic EPS | -7.44% | 5.70% | 18.13% | 32.40% | 35.76% |
| EPS Diluted | -7.26% | 6.09% | 18.28% | 30.31% | 34.33% |
| Normalized Diluted EPS | -7.44% | 5.70% | 18.13% | 32.40% | 35.76% |
| Average Basic Shares Outstanding | 26.90% | 38.06% | 45.57% | 53.55% | 57.63% |
| Average Diluted Shares Outstanding | 26.90% | 38.06% | 45.57% | 53.55% | 57.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |